INTRODUCTION {#s1}
============

Atrial fibrillation (AF) is the most common heart rhythm disease in the world, accounting approximately 0.5% of the total world population \[[@R1], [@R2]\]. AF exacerbates heart failure and ischemic stroke, substantially increases the morbidity and mortality, resulting in a higher burden for patients and even the nations. However, a higher incidence of adverse consequences for the elderly has been associated with atrial fibrillation. Although AF is a heterogeneous disease, previous reports suggest that the arrhythmia may arise due to the interaction by genetic and acquired risk factors - the so-called "double hit" hypothesis \[[@R3]\]. Unfortunately, the precise mechanisms of atrial remodeling were not well elucidated, leading to the demand of investigating the exact mechanisms of the disease and developing treatments. Identification of novel biomarker influencing the development of AF is critical to the understanding and future prevention of the disease. Long non-coding RNAs (lncRNAs) are a subclass of noncoding RNAs (ncRNAs) and are transcribed from the genome with at least 200 nucleotides \[[@R4], [@R5]\]. The ncRNAs include microRNAs (miRNAs), PIWI interacting RNAs, and endogenous small interfering RNAs. In fact, the notion of ncRNAs acting as heart disease modulators is not new; reviews regarding the role of ncRNAs in heart disease have already been published before \[[@R6]\]. It has become increasingly apparent that many of the lncRNAs play molecular functions, such as controlling cell cycle, differentiation, apoptosis or as smaller RNA precursors \[[@R6]-[@R8]\]. LncRNAs may function through a variety of mechanisms such as modulating gene transcription by rearranging chromosomal looping and transcription factor binding. LncRNAs also affect miRNA functions by controlling pre-mRNA splicing or as miRNA sponges. Recently, accumulating evidences indicate that there is aberrant expression of lncRNAs in many heart diseases, including heart failure, pathological hypertrophy and Ventricular Septal Defect etc \[[@R9]-[@R11]\]. However, to the best of our knowledge, no attempts have been made to investigate the possible involvement of lncRNAs expression in AF, and the underlying pathways remain poorly understood.

RESULTS {#s2}
=======

LncRNAs and mRNAs expression profiles in AF {#s2_1}
-------------------------------------------

LncRNA profiling showed 177 lncRNAs of 78243 tested with significant differential expression levels at least a two-fold change in AF patients compared with normal patients, with 100 up-regulated and 77 down-regulated, respectively. The top 25 differentially expressed lncRNAs were listed in Table [1](#T1){ref-type="table"}. Among the dysregulated lncRNA transcripts, NONHSAT098586 is the most up-regulated, with a fold of change (FC) of 7.51, whereas NONHSAT040387 is the most down-regulated, FC being 6.94. Using the same criteria as the lncRNAs, we found that 75 up-regulated and 78 down-regulated mRNA transcripts. The most up-regulated and downregulated mRNA transcripts are hemoglobin gamma A (NM_000559) and desmoplakin (NM_004415), with FCs of 16.03 and 14.84, respectively (shown in Table [2](#T2){ref-type="table"}). Hierarchical clustering of the lncRNA and mRNA profiles was performed using cluster 3.0.2; Hierarchical clustering of the expression of the 177 lncRNAs based on centered Pearson correlation clearly separated AF from normal control (Figure [1](#F1){ref-type="fig"}).

###### Top 25 aberrantly expressed lncRNAs in microarray for three pairs of AF and normal blood

  TargetID            FC (abs)   p      Regulation   N1      N2      N3      AF1     AF2     AF3     Chr     start       end
  ------------------- ---------- ------ ------------ ------- ------- ------- ------- ------- ------- ------- ----------- -----------
  NONHSAT098586       7.51       0.01   up           2.70    4.54    3.94    6.32    6.76    6.83    chr4    144918491   144940455
  NONHSAG007503       7.34       0.02   up           12.37   12.85   10.51   14.53   14.51   15.32   chr11   5246697     5248302
  NONHSAT040387       6.94       0.01   down         6.73    6.78    7.11    2.87    4.72    4.66    chr14   106068035   107099427
  NONHSAT076398       6.80       0.00   up           3.80    2.82    2.83    6.03    5.92    5.78    chr2    202316456   202323546
  NONHSAT053927       6.77       0.01   up           3.29    4.28    3.13    5.91    6.07    7.01    chr17   42338172    42345509
  NONHSAT098582       6.55       0.03   up           4.55    5.13    2.63    6.81    6.40    7.23    chr4    144917349   144940477
  NONHSAT040421       6.52       0.03   down         5.58    6.21    6.63    2.78    4.88    2.66    chr14   106329999   107034966
  NONHSAT017667       6.00       0.02   up           15.01   15.47   13.18   17.10   16.87   17.43   chr11   5246884     5248053
  TCONS_l2_00030433   5.25       0.00   down         7.66    8.28    8.29    5.06    5.70    6.29    chrX    3820106     3855883
  NONHSAT039492       5.21       0.01   down         10.72   10.45   9.85    7.62    8.70    7.57    chr14   96177059    96178299
  NONHSAT090718       5.15       0.04   up           5.35    3.08    3.59    6.91    6.67    5.53    chr3    93624883    93630001
  NONHSAG053956       5.03       0.00   down         7.97    8.40    8.26    5.63    5.64    6.36    chrX    3735557     3785832
  NONHSAT098591       4.92       0.00   up           4.05    3.48    3.56    5.95    5.77    6.26    chr4    145035828   145061788
  NONHSAT136136       4.81       0.00   down         7.29    7.70    7.72    4.75    5.16    6.01    chrX    3735579     3785832
  XR_245045.1         4.57       0.05   down         6.44    6.89    8.40    4.12    5.71    5.34                        
  NONHSAT141981       4.45       0.00   down         7.40    7.30    7.92    4.88    5.95    5.33    chr16   31973408    31985682
  NONHSAT142052       4.42       0.02   down         5.80    5.91    6.57    3.03    4.67    4.16    chr16   32926394    32926857
  NONHSAT076870       4.35       0.05   up           6.19    5.47    3.85    7.11    6.90    7.87    chr2    218678431   218680091
  NONHSAT040390       4.32       0.00   down         10.72   10.84   11.13   8.30    9.24    8.81    chr14   106111027   106478375
  ENST00000460164     4.18       0.03   down         13.24   12.64   13.65   9.98    11.83   11.51   14      106110833   106114892
  ENST00000456563     4.10       0.00   down         8.76    9.10    9.22    6.43    7.09    7.46    X       3772390     3785176
  NONHSAT040540       4.02       0.02   down         6.48    7.04    7.05    4.03    5.79    4.73    chr14   107108251   107108696
  NONHSAT076401       3.98       0.00   up           5.85    5.87    5.55    7.86    7.45    7.95    chr2    202343864   202345071
  NONHSAT136135       3.98       0.00   down         7.64    8.26    8.03    5.62    6.10    6.23    chrX    3735575     3742639
  NONHSAT055019       3.95       0.03   up           4.35    2.68    2.68    5.42    4.76    5.47    chr17   57695918    57696926

###### Top 25 aberrantly expressed mRNAs in microarray for three pairs of AF and normal blood

  Genbank Accession   Gene Name                                         FC (abs)   p      Regulation   N1      N2      N3      AF1     AF2     AF3
  ------------------- ------------------------------------------------- ---------- ------ ------------ ------- ------- ------- ------- ------- -------
  NM_000559           HBG1                                              16.03      0.01   up           4.97    7.33    4.25    9.98    9.40    9.18
  NM_000342           SLC4A1                                            14.84      0.00   up           3.15    4.55    2.77    7.31    6.75    8.09
  NM_003944           SELENBP1                                          9.25       0.02   up           4.31    5.50    2.77    6.99    6.99    8.22
  DQ656067            clone Affy2H6-6                                   8.66       0.02   up           4.87    6.87    4.49    8.68    8.77    8.11
  NM_000519           HBD                                               6.24       0.02   up           14.37   15.04   12.74   16.55   16.53   16.99
  NM_000517           HBA2                                              6.15       0.02   up           13.82   13.80   11.72   15.40   15.75   16.05
  NM_004415           DSP                                               6.09       0.00   down         5.35    5.51    5.75    2.93    3.09    2.77
  XM_003119591        uncharacterized LOC100508797                      5.80       0.04   down         7.52    6.98    7.42    3.18    5.75    5.39
  NM_007308           SNCA                                              5.76       0.01   up           10.48   10.84   9.37    12.80   12.44   13.04
  NM_000518           HBB                                               5.75       0.03   up           15.36   15.64   13.28   17.22   17.09   17.54
  NM_000032           ALAS2                                             4.88       0.04   up           6.45    8.03    5.64    8.44    9.55    8.99
  AY172958            anti-rabies SOJB immunoglobulin heavy chain       4.87       0.03   down         10.42   10.10   11.64   7.39    9.17    8.75
  NM_017414           USP18                                             4.60       0.01   down         7.63    6.71    6.10    4.15    5.01    4.67
  HCG1981372                                                            4.29       0.00   down         8.17    8.80    8.76    6.25    6.25    6.95
  XM_003403505        Ig kappa chain V-III region VH-like               4.27       0.01   down         9.61    9.56    9.87    6.65    8.18    7.93
  AY505570            Immunoglobulin heavy chain                        4.22       0.00   down         9.56    9.36    10.13   7.16    8.09    7.57
  A_33_P3331178                                                         4.21       0.02   down         7.63    7.74    8.20    5.28    6.77    5.29
  A_24_P110242                                                          3.99       0.03   down         9.48    9.72    10.90   7.39    8.80    7.93
  NM_002100           GYPB                                              3.93       0.00   up           3.44    3.56    3.67    5.33    5.53    5.73
  XM_003403854        Ig heavy chain V-III region VH26-like             3.92       0.01   down         10.49   10.46   10.82   7.74    9.06    9.06
  XM_003403466        Ig heavy chain V-I region V35-like                3.86       0.01   down         11.01   10.85   11.47   8.56    9.63    9.30
  Z46771              Immunoglobulin heavy chain VDJ region             3.85       0.00   down         9.15    9.07    9.73    6.94    7.87    7.31
  L03830              Ig rearranged H-chain mRNA V-region               3.84       0.01   down         8.62    8.70    8.86    6.21    7.50    6.66
  Z18824              Rearranged Ig H-chain V-domain                    3.83       0.01   down         8.56    8.75    9.56    6.46    7.65    6.95
  AY393117            Clone RA702-M1-22.fa Immunoglobulin heavy chain   3.78       0.01   down         9.71    9.68    10.13   7.40    8.51    7.85

![Heat map and hierarchical clustering of lncRNA profile comparison between the AF and normal blood samples\
Each row represents one lncRNA, and each column represents one sample. The relative lncRNA expression is depicted according to the color scale. Red indicates up-regulation; green indicates downregulation. 2.0 and −2.0 are fold changes in the corresponding spectrum, whereas left represents normal samples and right represents AF samples. The differentially expressed lncRNAs are clearly self-segregated into clusters.](oncotarget-07-10803-g001){#F1}

Validate the results of microarray by qPCR {#s2_2}
------------------------------------------

LncRNAs transcripts were validated by quantitative PCR with 30 human blood samples (20 AF samples and 10 control samples). Two lncRNAs (NONHSAG007503 and NONHSAT040387) were randomly selected to prove the consistency of microarray and qPCR. As expected, the expression of lncRNA NONHSAG007503 was up-regulated and NONHSAT040387 was down-regulated in the AF samples versus control samples (Figure [2](#F2){ref-type="fig"}), consistent with the microarray results.

![Comparisons between microarray data and qPCR results\
NONHSAG007503 **A.** and **B.** NONHSAT040387 were differentially expressed in AF samples compared with control samples detected by microarray and real-time quantitative PCR. The validation results of the lncRNAs indicated that the microarray data correlated well with the qPCR results. The results are presented as mean ± SEM (*n* = 3 in micro array, *n* = 10 in realtime PCR). \**p* \< 0.05 and \*\* *p* \< 0.01 *vs* corresponding controls.](oncotarget-07-10803-g002){#F2}

Go and pathway analysis {#s2_3}
-----------------------

To predict the functions of the lncRNAs, we adopted methods originally demonstrated in previous reported paper \[[@R12]\]. Generally, The GO category was classified by Fisher\'s exact test, and the *p*-value was corrected by the false discovery rate (FDR) calculation. The presenting key genes in gene networks and canonical pathways were identified by the curated Ingenuity Pathway Analysis (IPA) database according to KEGG. The enriched functional terms were used as the predicted functional terms for each given lncRNAs. GO analysis indicated that several functional pathways were enriched. Among these pathways, oxygen transporter activity, protein heterodimerization activity, and DNA binding were the most closely associated with AF (Figure [3A](#F3){ref-type="fig"}). Furthermore, using the same criteria as the GO analysis, KEGG Pathway analysis showed some corresponding pathways, including viral carcinogenesis, alcoholism, hematopoietic cell lineage, osteoclast differentiation and complement and coagulation cascades, etc. (Figure [3B](#F3){ref-type="fig"}).

![GO analysis\
**A.** and KEGG Pathway analysis **B.** of aberrantly expressed lncRNAs in AF.](oncotarget-07-10803-g003){#F3}

Construction of co-expression network {#s2_4}
-------------------------------------

To explore which lncRNAs and mRNAs play critical roles in AF progression, we constructed a co-expression network of the differentially expressed correlated lncRNAs and mRNAs. The correlation between lncRNAs and mRNAs was expressed with Pearson\'s correlation coefficients and those no less than 0.99 were used to construct the network. Transcriptional regulatory elements may exist in non-coding regions, but it could be tough to distinguish these only guiding by primary sequences. To explore lncRNAs that possibly have trans-regulating functions, we compared the mRNAs that coexpressed with these lncRNAs with those mRNAs including regulatory targets of certain Transcription factors (TFs). It can be helpful to accurately map the boundaries of regulatory elements because of the narrow transcription factor binding sites. As shown in Figure [4](#F4){ref-type="fig"}, GATA1 closely correlated with many mRNAs and lncRNAs. Similar results were showed in TAF7 and EBF1, indicating the three transcriptional regulatory elements may play critical roles in lncRNAs process.

![LncRNA-mRNA-network was constructed based on the correlation analysis between the differential expressed lncRNAs and mRNAs\
In the network, blue node represents Transcription factors, red node represents the lncRNAs, and green node represents the target mRNAs. The size of node is proportional to the outgoing link number. The thickness of outgoing link represents statistical relationship to the number of occurrences of the results proportionally.](oncotarget-07-10803-g004){#F4}

DISCUSSION {#s3}
==========

AF is the most common cardiac diseases, bringing huge burdens to old patients and their families. The prevalence of AF increases rapidly with age. However, the exact pathogenesis and serum biomarkers of AF are still not well elucidated. Sensitive serum biomarkers reflect the development of atrial remodeling, thus it could be simpler to determine the state of atrial remodeling and perform interventional therapy timely through observing serum biomarkers \[[@R13]\]. However, so far the correlation among lncRNAs, atrial remodeling and serum biomarkers remains unknown. To the best of our knowledge, this study is the first comprehensive lncRNAs analysis with AF in blood. This study was designed to discover the relationship between lncRNAs expression and atrial structural remodeling of AF. These data indicated that 177 lncRNAs displayed significant differential expression in AF. Functional elements are always identified by extreme conservative evolutionary sequences, but many lncRNAs are poorly conserved though they play roles in the heart. Ruan et al has discovered 219 lncRNAs differentially expressed in atrial tissues between AFs and controls \[[@R14]\]. Our study results are consisted with Ruan\'s study. For example, GO analysis found same changes in molecular function between AF compared with controls, including DNA binding, protein binding, metal ion binding and transforming growth factor beta binding. Differential expression of lncRNAs may be affected by AF and atrial remodeling and our work has identified the differentially expressed lncRNAs in AF. However, it needs further investigation to confirm the relationship between their expression and function. Subgroup analysis of lncRNAs should be performed to further exploration on the regulatory network. Unfortunately, available experimentally verified lncRNA associations are still comparatively rare, further functional studies are required to elucidate their roles in AF. These findings bring profound influences on cardiovascular science research and provide golden opportunities for intervention therapies in disease progression.

Cardiac science including development and adaptation regulatory networks has been intensively investigated. In the past ten years, with the help of development in molecular and biotechnology, scientists have achieved great progress in elucidating the molecular mechanisms of heart formation. In recent years, genetics research based on family and population showed that transcription factors may play important roles in arrhythmia susceptibility \[[@R14]-[@R16]\]. Moreover, animal studies have demonstrated that transcription factors performed crucial roles in atrial remodeling, indicating the importance of transcription factors in AF. In the present study, we found that several transcription factors such as GATA1, TAF7 and EBF1 could be essential for lncRNAs expression in AF development. Pathway identification showed that GATA1, TAF7 and EBF1 played central roles in AF, which were consistent with previous reports \[[@R17],[@R18]\]. Close physical links between lncRNAs and developmental functional genes does not necessarily indicate that there would be functional links between protein-coding genes and lncRNAs. For example, recent researches on mice suggested that there were no evident correlations between expression levels of lncRNAs and their adjacent genes \[[@R19]-[@R22]\]. Therefore, further researches are demanded to fully elucidate the molecular mechanisms between these transcription factors and AF pathogenesis. In the future, such researches can help making significant progress in the clinical treatment of arrhythmia.

In conclusion, we explored and found out the dysregulated expression of lncRNAs in human AF for the first time. These data suggest that a great variety of lncRNAs are involved in AF development and present background/reference resources for future exploring the functions of lncRNAs in AF development. More investigation will be required to define the physiologic functions and the mechanisms by which these lncRNAs affecting AF formation.

MATERIALS AND METHODS {#s4}
=====================

Ethics statement {#s4_1}
----------------

This research was permitted by the human ethics committee of the Shanghai Chest Hospital, People\'s Republic of China. All AF patients and health control people have been informed with written consent to use their blood samples for this study. The AF patients were elder adults (age=55±5 years), without hypertension, diabetes, hyperthyroidism and other heart disease.

Blood collection and RNA extraction {#s4_2}
-----------------------------------

5 ml blood of each person was collected and immediately stored at 4°C until use. According to the manufacturer\'s protocols, RNA Isolation Kit (Ambion, USA) was used to extract total RNA from blood samples within 24h after collection. Total RNA was quantified with the NanoDrop ND-2000 (Thermo Scientific, USA) and the RNA integrity was assessed using Agilent Bioanalyzer 2100 (Agilent Technologies, USA).

LncRNA and mRNA microarray expression profiling {#s4_3}
-----------------------------------------------

Agilent Human LncRNA Microarray v 4.0 is designed for the analysis of global human lncRNAs and protein-coding transcripts. The microarray profiling was conducted in the laboratory of the OE Biotechnology Company in Shanghai, People\'s Republic of China. The sample labeling, microarray hybridization and washing were performed as described by the manufacturer. In brief, total RNA were transcribed to cDNA, synthesized into cRNA embedding with Cyanine-3-CTP. These tagged cRNAs were hybridized onto the Human lncRNA array, including a global profiling of 78,243 human lncRNAs and 30,215 coding transcripts. The arrays were scanned with the Agilent Scanner G2505C (Agilent Technologies, USA) after washing. Array images were analyzed by Feature Extraction software (version 10.7.1.1, Agilent Technologies) and the raw data were extracted. The raw data were further analyzed by Genespring (Version 12.5, Agilent Technologies). The raw data were firstly normalized, setting a change threshold\>2.0 and *p* value\<0.05 for up- and down-regulated genes. Then, Hierarchical Clustering was employed to calculate the distinguishable lncRNA and mRNA expression patterns.

Functional group analysis {#s4_4}
-------------------------

The functions in biological pathways or GO terms of these closest coding genes were analyzed by Pathway and GO analyses Kyoto Encyclopedia of Genes and Genomes (KEGG) analysis according to the latest KEGG database (<http://www.genome.jp/kegg/>) was employed to determine the biological roles of these differentially expressed mRNAs. Significance is judged when p value (Hypergeometric-P value) is less than 0.05.

Co-expression network construction {#s4_5}
----------------------------------

To discover the potential targets of lncRNA, we analyzed the interaction between lncRNAs and corresponding transcription factors based on hypergeometric cumulative distribution function with the help of MATLAB 2012b (The MathWorks, USA). The graph of the lncRNAs-TFs network was drawn with the help of Cytoscape 3.01 (Agilent and IBS, USA). If the intersection of these two groups is large enough (*p* \< 0.01, calculated by hypergeometric cumulative distribution function and FDR \< 0.01, under the control of the Benjamini and Hochberg procedure), then we predict that these lncRNAs possibly participate in pathways regulated by these TFs. The recently released ENCODE data on TFs and their regulatory targets were used in our analysis

Real-time quantitative reverse transcription PCR {#s4_6}
------------------------------------------------

A two-step reaction process was used for quantification reverse transcription \[[@R21]\] and PCR. Each RT reaction consisted of 0.5 μg RNA, 2 μL of Primer Script Buffer, 0.5 μL of oligo dT, 0.5 μL of random 6 mers, 0.5 μL of Primer Script RT Enzyme Mix I (TaKaRa, Japan) and nuclease-free water to reach a volume of 10 μL. Reactions were performed in the GeneAmp^®^ PCR System 7500 (Applied Biosystems, USA) for 15 min at 37°C, then inactivation of RT by heating at 85°C for 5 s. Then the RT mix was diluted by 10-fold with nuclease-free water and stored at −20°C. While running real-time quantitative PCR, melting curve was analyzed to verify the specificity of the aimed PCR product. All experiments were done in triplicate. Glyceraldehyde-3-phosphate dehydrogenase was used as an endogenous control to normalize and using the 2-ΔΔCt method for lncRNAs expression calculation. The primer sequences were designed in the laboratory based on the DNA sequences and is shown: NONHSAG007503 (forwards primer GGAGAAGTCTGCCGTTAC; reverse primer TCAAAGAACCTCTGGGTCC) and NONHSAT040387 (forwards primer CTTCAGTAGCTCTGCTATGC; reverse primer AGAGTCTGCGTAGTATATGGTA).

Statistical analysis {#s4_7}
--------------------

All results were represented as the means ± SD or proportions. For comparisons, paired t-tests and unpaired t-tests were performed where appropriate. All graphs were plotting using GraphPad Prism 5.0 for Microsoft Windows (GraphPad Software, USA). Two-sided *p*-values were calculated by the SPSS 16.0 (SPSS, USA) and statistical significance was judged when *p* \< 0.05.
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